Radiation Oncology Department, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200127, China
NCT Number: NCT06762158
This study aims to examine the efficacy of the combination of neoadjuvant chemoradiotherapy and perioperative PD-1 inhibitor in patients with locally advanced esophageal squamous cell cancer and explore the predictive biomarkers for this regimen.
This study is active but is not currently recruiting participants.
18 year–75 year
All sexes
Interventional
Not applicable
Shanghai, Shanghai Municipality, 200127, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Neoadjuvant chemoradiotherapy:
Begins on the second day after the completion of concurrent chemoradiotherapy, and no later than one week. Toripalimab 240mg Q3W, for a total of two cycles.
Preoperative assessment is conducted 3 weeks after the last neoadjuvant immunotherapy, and surgery is performed within 4-6 weeks. All patients undergo minimally invasive radical esophagectomy, either McKeown or Ivor-Lewis, with extended two-field or three-field lymph node dissection.
Whether to undergo postoperative adjuvant immunotherapy is determined based on the pathological response. Patients with pCR are only observed without receiving adjuvant treatment, while those not reaching pCR receive one year of adjuvant Toripalimab.
Time frame: From date of surgery to 4 weeks later
absence of viable tumor cells in the resected cancer specimen(ypT0N0)
Time frame: 24 months
From date of treatment until the date of death from any cause or the date of disease progression, assessed up to 24 months.
RenJi Hospital
Other
Neoadjuvant Chemoradiotherapy Combined With Sequential Perioperative PD-1 Inhibitor for Locally Advanced Esophageal Squamous Cell Carcinoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07711470
Carcinoma, Carcinoma, Squamous Cell
Beijing, China
View Trial DetailsNCT07702253
Carcinoma, Carcinoma, Squamous Cell
Hong Kong
View Trial DetailsNCT07147361
Carcinoma, Carcinoma, Squamous Cell
Beijing, Beijing Municipality, China
View Trial DetailsNCT07682376
Carcinoma, Carcinoma, Squamous Cell
Harbin, Heilongjiang, China
View Trial Details